Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2025 Financial Results GlobeNewswire December 15, 2025 CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (the “Company“) (NASDAQ: QIPT; TSX:QIPT), a U.S.-based home medical equipment provider focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2025 financial results and […]

3 E Network Signed a Master Services Agreement with Orka Technologies to Develop a 26MW AI Data Center in Finland

3 E Network Signed a Master Services Agreement with Orka Technologies to Develop a 26MW AI Data Center in Finland GlobeNewswire December 15, 2025 HONG KONG, Dec. 15, 2025 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider

Quipt Home Medical Enters Into Definitive Agreement for Its Acquisition by Affiliates of Kingswood Capital Management and Forager Capital Management

Quipt Home Medical Enters Into Definitive Agreement for Its Acquisition by Affiliates of Kingswood Capital Management and Forager Capital Management GlobeNewswire December 15, 2025 Quipt shareholders to receive US$3.65 per share in cash Transaction provides immediate liquidity and certainty of value to shareholders The per share purchase price represents a 162% premium to Quipt's unaffected

Bitcoin Bancorp Plans Deployment of Up to 200 Licensed Bitcoin ATMs Across Texas Beginning Q1 2026

Bitcoin Bancorp Plans Deployment of Up to 200 Licensed Bitcoin ATMs Across Texas Beginning Q1 2026 Expansion Targets One of the Most Crypto-Friendly U.S. States as Part of a Broader National Growth Strategy GlobeNewswire December 15, 2025 LAS VEGAS, Dec. 15, 2025 (GLOBE NEWSWIRE) — Bitcoin Bancorp. (OTC: BCBC) (“Bitcoin Bancorp” or the “Company”), the

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering GlobeNewswire December 15, 2025 BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the withdrawal of

Green Rain Energy Holdings Inc. (OTCID: GREH) Extends Holiday Greetings to Shareholders

Green Rain Energy Holdings Inc. (OTCID: GREH) Extends Holiday Greetings to Shareholders GlobeNewswire December 15, 2025 BEVERLY HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Green Rain Energy Holdings Inc. (OTCID: GREH) (“Green Rain” or the “Company”) today announced that its management team and board of directors extend their sincere holiday wishes to all shareholders,

Almadex Commences Diamond Drilling at The New Hope Copper Porphyry Project, Arizona, USA and Grants Stock Options

Almadex Commences Diamond Drilling at The New Hope Copper Porphyry Project, Arizona, USA and Grants Stock Options GlobeNewswire December 15, 2025 VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce that it has started a scout exploration drill program at the Company's

Abeona Therapeutics(R) Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Abeona Therapeutics(R) Announces Appointment of Mohamad Tabrizi as Chief Business Officer GlobeNewswire December 15, 2025 CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 GlobeNewswire December 15, 2025 Data from FDA-advised study demonstrates Lumee(TM) Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin GlobeNewswire December 15, 2025 THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE

Scroll to Top